Bio-Techne Management
Management criteria checks 4/4
Bio-Techne's CEO is Kim Kelderman, appointed in Feb 2024, has a tenure of less than a year. total yearly compensation is $2.61M, comprised of 22.6% salary and 77.4% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth $2.27M. The average tenure of the management team and the board of directors is 2.3 years and 7.3 years respectively.
Key information
Kim Kelderman
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 22.6% |
| CEO tenure | less than a year |
| CEO ownership | 0.02% |
| Management average tenure | 2.3yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15
Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16Bio-Teche announces transition plan for CEO Kummeth
Aug 04Bio-Techne: Resiliency Comes At A Large Premium
Jul 29Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer
Jul 06Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?
Jun 22Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?
Jun 09Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
May 26Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)
May 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$224m |
| Sep 30 2023 | n/a | n/a | US$247m |
| Jun 30 2023 | US$3m | US$590k | US$285m |
| Mar 31 2023 | n/a | n/a | US$271m |
| Dec 31 2022 | n/a | n/a | US$262m |
| Sep 30 2022 | n/a | n/a | US$292m |
| Jun 30 2022 | US$3m | US$562k | US$272m |
| Mar 31 2022 | n/a | n/a | US$225m |
| Dec 31 2021 | n/a | n/a | US$210m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | US$4m | US$530k | US$140m |
| Mar 31 2021 | n/a | n/a | US$184m |
| Dec 31 2020 | n/a | n/a | US$175m |
| Sep 30 2020 | n/a | n/a | US$248m |
| Jun 30 2020 | US$2m | US$500k | US$229m |
| Mar 31 2020 | n/a | n/a | US$187m |
| Dec 31 2019 | n/a | n/a | US$195m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | US$2m | US$452k | US$96m |
| Mar 31 2019 | n/a | n/a | US$121m |
| Dec 31 2018 | n/a | n/a | US$96m |
| Sep 30 2018 | n/a | n/a | US$128m |
| Jun 30 2018 | US$2m | US$73k | US$126m |
Compensation vs Market: Kim's total compensation ($USD2.61M) is below average for companies of similar size in the US market ($USD13.53M).
Compensation vs Earnings: Kim's compensation has been consistent with company performance over the past year.
CEO
Kim Kelderman (55 yo)
less than a year
Tenure
US$2,605,712
Compensation
Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.61m | 0.023% $ 2.3m | |
| Executive VP of Finance & CFO | 10yrs | US$3.44m | 0.046% $ 4.6m | |
| Senior VP | 1.1yrs | US$1.04m | 0.0010% $ 105.7k | |
| Senior Advisor | less than a year | US$30.58m | 0.81% $ 81.9m | |
| President of Protein Sciences Segment | 2.3yrs | US$2.33m | 0.0028% $ 284.0k | |
| VP & CTO | less than a year | no data | no data | |
| Senior Director of Investor Relations & Corporate Development | no data | no data | no data | |
| Vice President of Sales and Marketing | no data | no data | no data | |
| Vice President of Corporate Development | 3.3yrs | US$1.37m | no data | |
| Senior VP & Chief Human Resources Officer | 2.3yrs | no data | no data | |
| Managing Director | 7.8yrs | no data | no data | |
| Senior VP & Chief Digital Officer | 6.3yrs | no data | no data |
2.3yrs
Average Tenure
54yo
Average Age
Experienced Management: TECH's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.61m | 0.023% $ 2.3m | |
| Independent Chairman of the Board | 21.3yrs | US$410.30k | 0.028% $ 2.8m | |
| Independent Director | 14.9yrs | US$300.30k | 0.023% $ 2.3m | |
| Independent Director | 7.3yrs | US$275.30k | 0.0078% $ 788.5k | |
| Independent Director | 34.3yrs | US$285.51k | 0.015% $ 1.6m | |
| Independent Director | 13.9yrs | US$290.30k | 0.027% $ 2.8m | |
| Independent Director | 3.8yrs | US$282.59k | 0.0036% $ 363.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$275.30k | 0.0050% $ 505.5k | |
| Independent Director | 7.3yrs | US$275.30k | 0.0078% $ 788.5k | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.3yrs
Average Tenure
62yo
Average Age
Experienced Board: TECH's board of directors are considered experienced (7.3 years average tenure).